The FDA’s recent decision to phase out mandatory animal testing marks a historic shift in drug development — and Qureator is ready. From the start, Qureator has championed human-relevant, next-generation platforms that better bridge lab models to patient outcomes. Our Curiochips™ organ-on-a-chip technology replicates complex human tissue environments with unparalleled precision, while Quricore™, our AI-powered analytics engine, accelerates preclinical insights and enhances translational success. Together, they offer biopharma partners a powerful solution for faster, more ethical, and more predictive research. As the industry moves beyond animal models, Qureator stands ready to help drive the future of safer, smarter drug development. Let’s shape this new era together.